These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38726640)

  • 1. How Labor Costs Affect Innovation Output in Pharmaceutical Companies: Evidence from China.
    Chen Y; He Q; Wang T
    Inquiry; 2024; 61():469580241246965. PubMed ID: 38726640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corporate financialization, financing constraints, and innovation efficiency-Empirical evidence based on listed Chinese pharmaceutical companies.
    Zhu J; Tang Y; Wei Y; Wang S; Chen Y
    Front Public Health; 2023; 11():1085148. PubMed ID: 37124778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Labor Costs, Market Environment and Green Technological Innovation: Evidence from High-Pollution Firms.
    Gong R; Wu YQ; Chen FW; Yan TH
    Int J Environ Res Public Health; 2020 Jan; 17(2):. PubMed ID: 31947618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Executive pharmaceutical background, R&D investment and corporate innovation performance.
    Zhang L; Li S; Wu M
    Am J Transl Res; 2023; 15(11):6576-6586. PubMed ID: 38074834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can rising labor costs boost private sector R&D investment? : Evidence from a survey of Chinese private firms.
    Deng C; Liu Y; Gu D
    PLoS One; 2022; 17(8):e0268287. PubMed ID: 35925924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does China's centralized volume-based drug procurement policy facilitate the transition from imitation to innovation for listed pharmaceutical companies? Empirical tests based on double difference model.
    Gu Y; Zhuang Q
    Front Pharmacol; 2023; 14():1192423. PubMed ID: 37324496
    [No Abstract]   [Full Text] [Related]  

  • 7. Digital finance and Chinese corporate labor investment efficiency: The perspective of financing constraints and human capital structure.
    Yang J; Jiang Y; Chen H; Gan S
    Front Psychol; 2022; 13():962806. PubMed ID: 36033042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of technological innovation on corporate leverage in China: The moderating role of policy incentives and market competition.
    Ren L; Liu D; Xiong D
    Front Psychol; 2022; 13():1068375. PubMed ID: 36533031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Government innovation subsidy, executives' academic capital and innovation quality: Evidence from pharmaceutical companies in China.
    Xia Y; Fan M; Zuo X; Hao W; Jia Y
    Front Psychol; 2022; 13():1092162. PubMed ID: 36710848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qualified foreign institutional investors and corporate innovation: From the perspective of corporate governance.
    Wang X; Wang W; Shi XY
    Front Psychol; 2022; 13():1005409. PubMed ID: 36467163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Environmental regulation, digital finance, and technological innovation: evidence from listed firms in China.
    Yang Y; Li X
    Environ Sci Pollut Res Int; 2023 Mar; 30(15):44625-44639. PubMed ID: 36696056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. State-owned capital and quality of green innovation: Evidence from Chinese listed private firms.
    Yan H; Chen Z; Yang Y
    Heliyon; 2024 Apr; 10(7):e28179. PubMed ID: 38560115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Financing innovation and enterprises' efficiency of technological innovation in the internet industry: Evidence from China.
    Piao Z; Lin Y
    PLoS One; 2020; 15(9):e0239265. PubMed ID: 32931512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategic management and organizational culture of medical device companies in relation to corporate performance.
    Park S; Kim HK; Lee HJ; Choi M; Lee M; Jakovljevic M
    J Med Econ; 2023; 26(1):781-792. PubMed ID: 37300440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Financial risk of the biotech industry versus the pharmaceutical industry.
    Golec J; Vernon JA
    Appl Health Econ Health Policy; 2009; 7(3):155-65. PubMed ID: 19799470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obstacles and opportunities in Chinese pharmaceutical innovation.
    Ni J; Zhao J; Ung CO; Hu Y; Hu H; Wang Y
    Global Health; 2017 Mar; 13(1):21. PubMed ID: 28340579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbon emission trading scheme and corporate labor investment efficiency: evidence from China.
    Ma J; Xiang Y; Bai X
    Environ Sci Pollut Res Int; 2023 Aug; 30(39):90830-90843. PubMed ID: 37462874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Financing Constraints and Firm's Productivity Under the COVID-19 Epidemic Shock: Evidence of A-Shared Chinese Companies.
    Wong Z; Chen A; Taghizadeh-Hesary F; Li R; Kong Q
    Eur J Dev Res; 2023; 35(1):167-195. PubMed ID: 35194343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Compensation Gap on Corporate Innovation: Evidence from China's Pharmaceutical Industry.
    Fu L; Zhang S; Wu F
    Int J Environ Res Public Health; 2022 Feb; 19(3):. PubMed ID: 35162779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Industrial technology progress, digital finance development and corporate risk-taking: Evidence from China's listed firms.
    Wu X; Liu Y; Xia B
    PLoS One; 2024; 19(3):e0298734. PubMed ID: 38489335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.